Abstract
The purpose of this study is to investigate the healing effect of Favipiravir used in pre-intensive care treatment of patients diagnosed with COVID-19 in order to elucidate the pathogenesis and complications of coronavirus. The data regarding the clinical findings of the patients in the hospital information system and the biochemical parameters made standard in the treatment/follow-up of COVID 19 were taken from the system and evaluated retrospectively. In addition, it was examined as a whole with mild, moderate and severe pulmonary involvement compared to CT findings. Hemogram, coagulation and biochemistry parameters used in the diagnosis and follow-up of COVID-19 were evaluated. SPSS 22.0 statistics program for Windows was used in statistical analysis to evaluate the data obtained from patient files and hospital information system. There is no definitive treatment protocol within the scope of treatment. Drug studies are currently ongoing. In this study, the first clinical findings, treatment types and recovery times of patients diagnosed with COVID-19, the healing effect of favipiravir used before intensive care were determined. Between group 1 (those who started treatment within 0-5 days) and group 2 (those who started treatment within 6-10 days), after 5 days of favipravir treatment, when serum parameters were compared, favipravir treatment was statistically significantly lower in the first group that was started early, WBC, Neutrophil, Creatine, CK, CRP, D-Dimer, PCT, LDH. By collecting the data obtained as a result of the research, early deaths can be prevented worldwide. Our study recommending alternative treatment approaches is important for the protection of patients' quality of life. In this study, when all biochemical markers were evaluated together, it was evaluated that starting Favipiravir treatment early was beneficial in treating COVID-19 disease.
There is no Figure or data content available for this article
References
2. Bugert JJ, Hucke F, Zanetta P, Bassetto M, Brancale A. Antivirals in medical biodefense. Virus Genes. 2020;56(2):150-167. doi:10.1007/s11262-020-01737-5
3. Furuta Y, Takahashi K, Shiraki K, et al. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 2009;82(3):95-102. doi:10.1016/j.antiviral.2009.02.198
4. Delang L, Segura Guerrero N, Tas A, et al. Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. J Antimicrob Chemother. 2014;69(10):2770-2784. doi:10.1093/jac/dku209
5. Goldhill DH, te Velthuis AJW, Fletcher RA, et al. The mechanism of resistance to favipiravir in influenza. Proc Natl Acad Sci. 2018;115(45):11613-11618. doi:10.1073/pnas.1811345115
6. Janowski AB, Dudley H, Wang D. Antiviral activity of ribavirin and favipiravir against human astroviruses. J Clin Virol. 2020;123:104247. doi:10.1016/j.jcv.2019.104247
7. Takayama-Ito M, Saijo M. Antiviral Drugs Against Severe Fever With Thrombocytopenia Syndrome Virus Infection. Front Microbiol. 2020;11. doi:10.3389/fmicb.2020.00150
8. Tani H, Fukuma A, Fukushi S, et al. Efficacy of T-705 (Favipiravir) in the Treatment of Infections with Lethal Severe Fever with Thrombocytopenia Syndrome Virus. Duprex WP, ed. mSphere. 2016;1(1). doi:10.1128/mSphere.00061-15
9. Dawes BE, Kalveram B, Ikegami T, et al. Favipiravir (T-705) protects against Nipah virus infection in the hamster model. Sci Rep. 2018;8(1):7604. doi:10.1038/s41598-018-25780-3
10. Lo MK, Jordan R, Arvey A, et al. GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. Sci Rep. 2017;7(1):43395. doi:10.1038/srep43395
11. Baranovich T, Wong S-S, Armstrong J, et al. T-705 (Favipiravir) Induces Lethal Mutagenesis in Influenza A H1N1 Viruses In Vitro. J Virol. 2013;87(7):3741-3751. doi:10.1128/JVI.02346-12
12. Kiso M, Takahashi K, Sakai-Tagawa Y, et al. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci. 2010;107(2):882-887. doi:10.1073/pnas.0909603107
13. Watanabe T, Kiso M, Fukuyama S, et al. Characterization of H7N9 influenza A viruses isolated from humans. Nature. 2013;501(7468):551-555. doi:10.1038/nature12392
14. Madelain V, Nguyen THT, Olivo A, et al. Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials. Clin Pharmacokinet. 2016;55(8):907-923. doi:10.1007/s40262-015-0364-1
15. Nguyen THT, Guedj J, Anglaret X, et al. Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. Horby PW, ed. PLoS Negl Trop Dis. 2017;11(2):e0005389. doi:10.1371/journal.pntd.0005389
16. Favipiravir 200 Mg Tablets Prospectus.; 2020.
17. Results D. Avigan Tablet 200 Mg.; 2020.
18. Republic of Turkey Ministry of Health, General Directorate of Public Hospitals, Supply Planning, Stock And Logistics Management Department HPMU. In The Treatment of Covıd-19 (SARS-CoV2 Infection) Informatıon on Medications to Be Used.; 2020.
19. Yamada K, Noguchi K, Kimitsuki K, et al. Reevaluation of the efficacy of favipiravir against rabies virus using in vivo imaging analysis. Antiviral Res. 2019;172:104641. doi:10.1016/j.antiviral.2019.104641
20. FURUTA Y, KOMENO T, NAKAMURA T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Japan Acad Ser B. 2017;93(7):449-463. doi:10.2183/pjab.93.027
How to Cite This
Article Metrics
Download Statistics
Downloads
Other Statistics
Copyright and Permissions
Publishing your paper with Jurnal Teknologi Laboratorium (JTL) means that the author or authors retain the copyright in the paper. JTL granted an exclusive reuse license by the author(s), but the author(s) are able to put the paper onto a website, distribute it to colleagues, give it to students, use it in your thesis etc, even commercially. The author(s) can reuse the figures and tables and other information contained in their paper published by JTL in future papers or work without having to ask anyone for permission, provided that the figures, tables or other information that is included in the new paper or work properly references the published paper as the source of the figures, tables or other information, and the new paper or work is not direct at private monetary gain or commercial advantage.
JTL journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This journal is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets others remix, transform, and build upon the material for any purpose, even commercially.
JTL journal Open Access articles are distributed under this Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA). Articles can be read and shared for All purposes under the following conditions:
- BY: You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- SA: If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.